Characterization of "zinc finger E-box–binding homeobox 1 (ZEB1)"-mediated epithelial-mesenchymal transition (EMT) in glioblastoma (GBM) with respect to molecular subtypes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004577

Enrollment

Registered

2012-11-30

Start date

2012-12-14

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma multiforme C71

Interventions

Group 1: A library of primary glioma cell lines will be generated. Clinical and radiological (follow-up) data will be correlated to the molecular properties of the tumor.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - keine Volljährigkeit

Exclusion criteria

Exclusion criteria: - < 18 years of age

Design outcomes

Primary

Measure	Time frame
Survival time (from time of diagnosis). The goal of the current study is to investigate mechanisms of tumor cell invasion in GBM of different transcriptional subtypes. We aim to establish a panel of primary glioma cell lines from patient biopsies in serum-free cell culture and to characterize them with respect to genomic mutations and transcriptional subtypes (Verhaak 2010, Phillips 2006). Additionally, clinical, radiological and histological data will be registered in order to comprehensively characterize the cell lines. Thus, the study should be classified as a prospective observational trial in order to register survival time which is defined as primary endpoint. Secondary endpoints are radiological or clinical tumor recurrence after first line therapy.	—

Measure

Time frame

Survival time (from time of diagnosis). The goal of the current study is to investigate mechanisms of tumor cell invasion in GBM of different transcriptional subtypes. We aim to establish a panel of primary glioma cell lines from patient biopsies in serum-free cell culture and to characterize them with respect to genomic mutations and transcriptional subtypes (Verhaak 2010, Phillips 2006). Additionally, clinical, radiological and histological data will be registered in order to comprehensively characterize the cell lines. Thus, the study should be classified as a prospective observational trial in order to register survival time which is defined as primary endpoint. Secondary endpoints are radiological or clinical tumor recurrence after first line therapy.

—

Secondary

Measure	Time frame
clinical or radiological tumor recurrence	—

Countries

Germany

Contacts

Public ContactPhilipp Euskirchen

Charité Universitätsmedizin Berlin Klinik für Neurologie

philipp.euskirchen@charite.de(030) 450560635

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026